Literature DB >> 9709924

Clinical and economic impact of implementing a comprehensive diabetes management program in managed care.

R J Rubin1, K A Dietrich, A D Hawk.   

Abstract

Diabetes mellitus places a significant burden on the U.S. healthcare system. Because of the potential to reduce diabetic complications and costs through intensive management, diabetes has become a primary target for disease management programs. We performed a retrospective analysis of short-term baseline and follow-up clinical, economic, and member and provider satisfaction data from approximately 7,000 people with diabetes being treated through seven managed care plans using Diabetes Treatment Centers of America's Diabetes NetCare, (Nashville, TN), a comprehensive diabetes management program. Our analysis indicates that Diabetes NetCare achieved gross economic adjusted savings of $50 per diabetic member per month (12.3%), with gross unadjusted savings of $44 (10.9%) per diabetic member per month. Hospital admissions per 1,000 diabetic member years decreased by 18%, and bed days fell by 21%. Patients with diabetes were more likely to get HbAlc tests, foot exams, eye exams, and cholesterol screenings while enrolled in the program. These data suggest that implementation of a comprehensive healthcare management program for people with diabetes can lead to substantial improvements in costs and clinical outcomes in the short-term. It is expected that improvements will increase over time, with continuing improvements in health status and a reduction in the number of future diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9709924     DOI: 10.1210/jcem.83.8.5075

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  Disease management in the American market.

Authors:  T Bodenheimer
Journal:  BMJ       Date:  2000-02-26

2.  Crossing the evidence chasm: building evidence bridges from process changes to clinical outcomes.

Authors:  David C Kendrick; Davis Bu; Eric Pan; Blackford Middleton
Journal:  J Am Med Inform Assoc       Date:  2007-02-28       Impact factor: 4.497

3.  Therapeutic lifestyle and disease-management interventions: pushing the scientific envelope.

Authors:  David A Alter
Journal:  CMAJ       Date:  2007-10-09       Impact factor: 8.262

4.  Use of chronic disease management programs for diabetes: in Alberta's primary care networks.

Authors:  David J T Campbell; Peter Sargious; Richard Lewanczuk; Kerry McBrien; Marcello Tonelli; Brenda Hemmelgarn; Braden Manns
Journal:  Can Fam Physician       Date:  2013-02       Impact factor: 3.275

Review 5.  Glipizide. A review of the pharmacoeconomic implications of the extended-release formulation in type 2 diabetes mellitus.

Authors:  R H Foster; G L Plosker
Journal:  Pharmacoeconomics       Date:  2000-09       Impact factor: 4.981

6.  Case-control study of 10 years of comprehensive diabetes care.

Authors:  J B Brown; G A Nichols; H S Glauber
Journal:  West J Med       Date:  2000-02

Review 7.  Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  Antona J Wagstaff; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Diabetes education: quality improvement interventions through health departments.

Authors:  Angela T Dearinger; Richard C Ingram; Robin P Pendley; Sarah Wilding
Journal:  Am J Prev Med       Date:  2013-12       Impact factor: 5.043

9.  Health care resource utilization associated with a diabetes center and a general medicine clinic.

Authors:  Elbert S Huang; Suzanne Gleason; Ronald Gaudette; Enrico Cagliero; Patricia Murphy-Sheehy; David M Nathan; Daniel E Singer; James B Meigs
Journal:  J Gen Intern Med       Date:  2004-01       Impact factor: 5.128

Review 10.  Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. A conceptual model.

Authors:  Catherine Kim; Timothy P Hofer; Eve A Kerr
Journal:  J Gen Intern Med       Date:  2003-10       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.